Cymabay Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

CymaBay Therapeutics

15/11/2022 02:48

* Cymabay Therapeutics Inc  CBAY.OQ  reported a quarterly
adjusted
loss of 28 cents​​ per share for the quarter ended in September.
The mean expectation of nine analysts for the quarter was for a
loss of 30 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Cymabay Therapeutics Inc's reported EPS for the quarter
was a
loss of 28 cents​.
    * The mean earnings estimate of analysts had fallen by
about 0.4%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Cymabay Therapeutics Inc shares had risen by 1.4% this
quarter and gained 5.0% so far this year.
    * The company reported a quarterly loss of $24.51 million.
    * Wall Street's median 12-month price target for Cymabay
Therapeutics Inc is $9.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
15 at 02:48 a.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.30          -0.28          Beat
 Jun. 30 2022      -0.30          -0.31          Missed
 Mar. 31 2022      -0.31          -0.32          Missed
 Dec. 31 2021      -0.26          -0.34          Missed